Open an account

Veradigm

MDRX · OTC

$4.75−$0.25 (−5.00%)TodayMarket closed ·
Prev close $5.00

About MDRX

Veradigm, Inc. engages in the provision of clinical, financial, and operational results services. The company is headquartered in Chicago, Illinois and currently employs 2,450 full-time employees. The firm's Veradigm Network provides advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. Its portfolio offers comprehensive solutions that help clients to advance healthcare by providing electronic health records (EHR), financial management, population health management, deidentified data and patient communication solutions. Its Provider business consists of two EHRs, practice management and revenue cycle management, which are patient engagement and enterprise resource planning solutions. Its Payer business delivers end-to-end solutions for health plans, from analytics and data to engagement solutions. Its Life Science Business includes a data and research platform and a commercial media business, which partners with life science and other healthcare companies and their respective brand agencies to deliver media, advertising and education to clinicians.

Employees
2,450
Headquarters
Chicago, Illinois
Listed
Jul 23, 1999
Sector
Health Care
Industry
Health Care Technology
Website
veradigm.com

MDRX key statistics

Market cap
808.86M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
75.89K
Volume
1.02M
Open price
$4.76
High today
$4.76
Low today
$4.00
52 Week high
$6.00
52 Week low
$3.25

Veradigm (MDRX) at a glance

Veradigm (MDRX) last traded at $4.75, with a market cap of 808.86M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.00 and $4.76. The current price is 18.8% above the day's low and 0.1% below its high.

Volume so far is 1.02M shares, above the average of 75.89K shares a day.

Over the past year Veradigm has ranged from $3.25 to $6.00, and now sits 55% of the way up that range.

Veradigm met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY22 it reported $0.22 per share against an estimate of $0.2856.

MDRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 45.5% on average.

  1. Q1 FY21: reported $0.19 per share against an estimate of $0.1569
  2. Q2 FY21: reported $0.23 per share against an estimate of $0.1778
  3. Q3 FY21: reported $0.27 per share against an estimate of $0.187
  4. Q4 FY21: reported $0.79 per share against an estimate of $0.3287
  5. Q1 FY22: reported $0.13 per share against an estimate of $0.2159
  6. Q2 FY22: reported $0.18 per share against an estimate of $0.1545
  7. Q3 FY22: reported $0.23 per share against an estimate of $0.1894
  8. Q4 FY22: reported $0.22 per share against an estimate of $0.2856

MDRX news

  • Press releaseBusiness Wire

    Veradigm Announces Updated Presentation Time for Upcoming Investor Conference

  • Press releasePRNewswire

    Did Veradigm Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Press releaseBusiness Wire

    Veradigm to Participate in Two Upcoming Investor Conferences

  • Press releaseBusiness Wire

    Veradigm Files 2023 and 2024 Form 10-K

  • Press releaseBusiness Wire

    Veradigm to Release Business Update May 26th and Host Investor Call May 27th

  • Press releaseBusiness Wire

    Veradigm Launches Health Network Architecture to Level the Playing Field for Independent Practices

  • Press releaseBusiness Wire

    Veradigm Survey: Independent Practices Rely on Technology to Stay Independent

  • Press releaseBusiness Wire

    Veradigm Receives KLAS 2026 Points of Light Award for Embedding SDOH Data in Provider EHR Workflows

Similar companies

Companies in the same industry as Veradigm

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.